13F filer · CIK 1646343
NEXTHERA CAPITAL LP
NEW YORK, NY · filing since Q4 2015 · last filing Aug 14, 2019
Reported value
$162.7M
+$47.2M vs prior
Positions
33
New / sold out
12 / 14
Added / reduced
10 / 9
Turnover
29.2%
buys $76.9M · sells $40.7M
Top-10 weight
69.1%
Biggest buys vs Q2 2016
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | SPDR S&P Biotech ETFPUT | +400,000 | – | +$26.5M |
| New | AstraZeneca PLCCALL | +250,000 | – | +$8.2M |
| New | Clovis Oncology Inc | +120,000 | – | +$4.3M |
| Added | Acceleron Pharma Inc | +118,817 | +120.0% | +$4.3M |
| New | Immunomedics Inc | +1,263,276 | – | +$4.1M |
| New | CoLucid Pharmaceuticals Inc | +100,000 | – | +$3.8M |
| Added | Eiger BioPharmaceuticals Inc | +250,000 | +1785.7% | +$3.3M |
| New | Zogenix Inc | +260,000 | – | +$3.0M |
| New | Ascendis Pharma A/S | +146,200 | – | +$2.9M |
| New | Neuroderm Ltd | +131,000 | – | +$2.4M |
12 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q2 2016
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | Mylan NV | -140,000 | -100.0% | $-6.1M |
| Reduced | GlaxoSmithKline PLC | -125,000 | -26.6% | $-5.4M |
| Sold out | Amgen Inc | -30,000 | -100.0% | $-4.6M |
| Sold out | Cynapsus Therapeutics Inc | -244,310 | -100.0% | $-4.1M |
| Reduced | Aerie Pharmaceuticals Inc | -60,280 | -54.7% | $-2.3M |
| Reduced | Seattle Genetics Inc | -40,000 | -26.4% | $-2.2M |
| Reduced | Aquinox Pharmaceuticals Inc | -158,300 | -31.8% | $-2.1M |
| Sold out | Array BioPharma Inc | -521,000 | -100.0% | $-1.9M |
| Reduced | Lannett Co Inc | -63,000 | -27.4% | $-1.7M |
| Sold out | Edge Therapeutics Inc | -135,836 | -100.0% | $-1.4M |
13 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q3 2016
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | SPDR S&P Biotech ETFPUTPUT | 400,000 | $26.5M | 16.29% |
| 2 | Pfizer IncCOM | 654,051 | $22.2M | 13.61% |
| 3 | GlaxoSmithKline PLCSPONSORED ADR | 345,000 | $14.9M | 9.14% |
| 4 | Shire PLCSPONSORED ADR | 67,000 | $13.0M | 7.98% |
| 5 | AstraZeneca PLCCALLCALL | 250,000 | $8.2M | 5.05% |
| 6 | Acceleron Pharma IncCOM | 217,817 | $7.9M | 4.84% |
| 7 | Seattle Genetics IncCOM | 111,500 | $6.0M | 3.70% |
| 8 | Insmed IncCOM PAR $.01 | 322,044 | $4.7M | 2.87% |
| 9 | Adamas Pharmaceuticals IncCOM | 278,740 | $4.6M | 2.81% |
| 10 | Aquinox Pharmaceuticals IncCOM | 340,000 | $4.5M | 2.79% |
23 more rows. Subscribe for $29/month to see every row, download the data and use the API.